Executive Interviews
-
Moving Beyond AAV: The Next Generation Of Vectors In CGT
12/1/2023
We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.
-
Top 2024 Clinical Trial Site Challenges: Staffing & Technology
12/1/2023
Industry experts talk about some of the new challenges facing clinical trial sites in 2024.
-
Building A Business Model For Novel Antibiotics
11/1/2023
In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.
-
The Power Couple Behind Krystal Biotech
11/1/2023
Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.
-
Life Biosciences Grows Up: A Q&A With Jerry McLaughlin
10/2/2023
Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.
-
Using AI To Find And Develop Safer Medicines
10/2/2023
Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.
-
Taking A Fresh Approach To Finance At BMS
9/1/2023
A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.
-
To America, A New Biopharma Model
9/1/2023
Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.
-
Biotech Veteran Pushes New Science And Regulatory Change
9/1/2023
Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.
-
Vincerx Pharma: Finding Strength In Symbiosis
8/1/2023
Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.